Cargando…

Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial

Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless...

Descripción completa

Detalles Bibliográficos
Autores principales: Duputel, Benjamin, Stallard, Nigel, Montestruc, François, Zohar, Sarah, Ursino, Moreno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521165/
https://www.ncbi.nlm.nih.gov/pubmed/36919403
http://dx.doi.org/10.1177/09622802231160554
_version_ 1785110075154628608
author Duputel, Benjamin
Stallard, Nigel
Montestruc, François
Zohar, Sarah
Ursino, Moreno
author_facet Duputel, Benjamin
Stallard, Nigel
Montestruc, François
Zohar, Sarah
Ursino, Moreno
author_sort Duputel, Benjamin
collection PubMed
description Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless, in which the two phases are separated into two independent studies, and inferentially seamless, in which the interim analysis is considered an adaptation of the study. Bayesian designs are scarcely studied. Our aim is to propose and compare Bayesian operationally seamless Phase II/III designs using a binary endpoint for the first stage and a time-to-event endpoint for the second stage. At the end of Phase II, arm selection is based on posterior (futility) and predictive (selection) probabilities. The results of the first phase are then incorporated into prior distributions of a time-to-event model. Simulation studies showed that Bayesian operationally seamless designs can approach the inferentially seamless counterpart, allowing for an increasing simulated power with respect to the operationally frequentist design.
format Online
Article
Text
id pubmed-10521165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-105211652023-09-27 Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial Duputel, Benjamin Stallard, Nigel Montestruc, François Zohar, Sarah Ursino, Moreno Stat Methods Med Res Original Research Articles Master protocol designs allow for simultaneous comparison of multiple treatments or disease subgroups. Master protocols can also be designed as seamless studies, in which two or more clinical phases are considered within the same trial. They can be divided into two categories: operationally seamless, in which the two phases are separated into two independent studies, and inferentially seamless, in which the interim analysis is considered an adaptation of the study. Bayesian designs are scarcely studied. Our aim is to propose and compare Bayesian operationally seamless Phase II/III designs using a binary endpoint for the first stage and a time-to-event endpoint for the second stage. At the end of Phase II, arm selection is based on posterior (futility) and predictive (selection) probabilities. The results of the first phase are then incorporated into prior distributions of a time-to-event model. Simulation studies showed that Bayesian operationally seamless designs can approach the inferentially seamless counterpart, allowing for an increasing simulated power with respect to the operationally frequentist design. SAGE Publications 2023-03-15 2023-05 /pmc/articles/PMC10521165/ /pubmed/36919403 http://dx.doi.org/10.1177/09622802231160554 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Articles
Duputel, Benjamin
Stallard, Nigel
Montestruc, François
Zohar, Sarah
Ursino, Moreno
Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title_full Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title_fullStr Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title_full_unstemmed Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title_short Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial
title_sort using dichotomized survival data to construct a prior distribution for a bayesian seamless phase ii/iii clinical trial
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521165/
https://www.ncbi.nlm.nih.gov/pubmed/36919403
http://dx.doi.org/10.1177/09622802231160554
work_keys_str_mv AT duputelbenjamin usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial
AT stallardnigel usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial
AT montestrucfrancois usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial
AT zoharsarah usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial
AT ursinomoreno usingdichotomizedsurvivaldatatoconstructapriordistributionforabayesianseamlessphaseiiiiiclinicaltrial